EUROPEAN DISCOVERY FOR SOLIDARITY: AN ADAPTIVE PANDEMIC AND EMERGING INFECTION PLATFORM TRIAL
THE EU-SOLIDACT TRIAL

INVESTIGATIONAL MEDICINAL PRODUCT (IMP) HANDLING MANUAL

Prepared by:			
Name: Gine Bakkehøi		Role: Drug Responsible/Pharmacist	
Signature:	Gine Bakkehøi Digitally signed by Gine Bakkehøi Date: 2021.06.29 13:50:44 +02'00'	Date:	29-JUN-2021
Reviewed by:			
Name: Inge Christoffer Olsen		Role: Head of Operations	
Signature:	Inge Christoffer Olsen Digitally signed by Inge Christoffer Olsen DN: cn=Inge Christoffer Olsen, o=Oslo University Hospital, ou=Dept. of Research Support for Clinical Trials, email=i.c.olsen@medisin.uio.no, c=NO Date: 2021.06.29 13:41:35 +02'00'	Date:	29-JUN-2021

VERSION 1.0
DATE: 29 JUN 2021

1 INVESTIGATIONAL MEDICINAL PRODUCT

1.1 Description of the Investigational Medicinal Product (IMP)

Baricitinib 2 mg filmcoated tablets or placebo will be provided in bottles each containing 36 filmcoated tablets. Each patient will be allocated one bottle.

Supplier: Eli Lilly
Contract Manufacturing Organization responsible for labelling, packaging and distribution:
Theradis Pharma, 41-45 chemin des Presses, 06800 Cagnes-sur-Mer, France

Responsible for data management and eCRF including ordering of study drugs through the eCRF: Inserm, France

Example of wrap-around label:



2 comprimés une fois par jour pendant l'hospitalisation, mais pas plus de 14 jours. Adaptation de la dose en raison de l'interaction médicamenteuse et de la fonction rénale selon le protocole spécifique au baricitinib.
À administrer par voie orale avec ou sans nourriture

2 tablets (2 x 2 mg) once daily while hospitalized but not more than 14 days. Dose adjustments due to drug interactions and decreased renal function according to baricitinib-specific protocol.
To be given orally with or without food

Oslo University Hospital, Sognsvannsveien 20, 0372 Oslo, Norway, Tel.: +47 91502770

EU-SolidAct - EudraCT: 2021-000541-41

Comprimés pelliculés de 2 mg de Baricitinib ou placebo
Voie Orale -1 flacon de 36 comprimés pelliculés
Pour essai clinique uniquement
A conserver à température ambiante (entre +10°C et +30°C)
Tenir hors de la portée des enfants

Baricitinib 2 mg film-coated tablets or placebo
Oral use - 1bottle contains 36 film-coated tablets.
For clinical trial use only.
Store at room temperature (+10°C/+30°C)
Keep out of reach of children FR/IE/NO

N° de Lot/Batch Nb: P99999
N° de Kit/Kit Nb: 9999
Date d'expiration/ Expiry date: DD/MMM/YYYY
Investigateur/Investigator: _____
N° Centre/Site Nb: _____
N° Patient/Patient ID: _____
Date dispensation/Dispensation date: /_____/_____/_____/

Investigator, Site number, Patient ID and Date of dispensation will be filled in by the site.

Example of booklet label:



EU-SolidAct - EudraCT: 2021-000541-41
Baricitinib 2 mg film-coated tablets or placebo
(I): _____
(II): _____
(III): _____
(VII): _____
(IV): P99999
(V): 9999
(VI): DD/MMM/YYYY

Czech čeština (CZ)..... 3
Deutsch (AT-LU)..... 4
Deutsch (DE)..... 5
English (IE-NO) 6
Español (ES)..... 7
ελληνικά (GR) 8
Français (BE-FR-LU) 9
Italiano (IT) 10
Magyar (HU) 11
Nederlands (BE) 12
Polski (PL) 13
Português (PT).....14
Slovenský jazyk (SK) 15

Oslo University Hospital, Sognsvannsveien 20, 0372 Oslo, Norway
Tel.: +47 91502770



EU-SolidAct EudraCT No.: 2021-000541-41
Baricitinib 2 mg film-coated tablets or placebo - Oral Use
1 bottle contains 36 film-coated tablets.
For information below, see the front page:
(I) Investigator (IV) Batch No. (VII) Date of dispensation
(II) Site (V) Kit No.
(III) Patient ID (VI) Expiry date
Store at room temperature (+10°C/+30°C)
2 tablets (2 x 2 mg) once daily while hospitalized but not more than 14 days.
Dose adjustments due to drug interactions and decreased renal function according to baricitinib-specific protocol.
To be given orally with or without food
Keep out of reach of children - For clinical trial use only
Oslo University Hospital, Sognsvannsveien 20, 0372 Oslo, Norway
Tel.: +47 91502770 *ENGLISH / IE-NO* ⑥

1.2 Supply of the IMP

The sponsor will provide study drugs to the sites as soon as the monitor confirms all essential documents (site agreement, regulatory and ethical approvals, signed protocol signature page, delegation log, GCP-training and protocol training for critical site staff, and eCRF access) for initiation are in place at the site. Before the order to Theradis Pharma is sent, Inserm will confirm that the site has access to the eCRF and that the unblinding procedure is signed.

The monitor will send the green light document to the lead monitor and to solidact@ous-hf.no. The lead monitor will make sure that the procedure is understood correctly and forward the green light document to Inserm. The green light document received at Inserm triggers ordering of study drugs from Theradis Pharma. The monitor may in some cases send the green light document directly to Inserm, but this will be upon agreement with the lead monitor.

Ordering of study drugs happens automatically through the green light process, and the sites do not have to do anything. Technically, the drug ordering will be done by Inserm.
Orders which arrive at Theradis Pharma by 4 pm (16:00) will be handled the following working day.
Theradis Pharma will ship the study drugs from Monday to Thursday.
The shipment from Theradis Pharma to the site will usually take 24 – 48 hours.
The initial supply at each site will be 10 bottles.

The sponsor will provide resupplies when necessary. The resupply will happen automatically for each site. Technically the ordering of resupply will be done by Inserm based on recruitment rate at the site (number of included patients and bottles used).

1.3 Receipt of IMP

The shipment will be accompanied by an Acknowledgement of Receipt (AoR) and a temperature logger.
The pharmacy/site must:

- Confirm the receipt by filling in the AoR and sending it to solidact@theradispharma.com as soon as possible and within 24 h of reception.
- Download the temperature readings for each delivery and send the temperature readings to solidact@theradispharma.com as soon as possible and within 24 h after reception.
- Report any anomaly (deviation), for instance temperature excursions, damaged products and/or lost products to solidact@theradispharma.com and solidact@ous-hf.no as soon as possible and within 24 h of reception.
- Report any product complaints to solidact@ous-hf.no as soon as possible and within 24 h. A product complaint could be any type of complaint involving the possible failure to meet specifications or any dissatisfaction with the design, packaging or labelling of the product.
- In case of emergency, for instance product complaints which can lead to recall (e.g. suspicion of falsified medicines) call telephone no. +47 91502770 (switchboard, Oslo University Hospital) as soon as possible and ask for one of the persons in the sponsor team. The names and contact details of the members of the sponsor team can be found in the Investigator Site File.
- Inform the Principal Investigator/site personnel of the delivery as soon as possible after reception.

1.3.1 Flow of the IMP management through the eCRF

- Inserm creates orders in the eCRF for study drugs to be sent to a site (blocks of 10).
- Alert e-mail goes from Inserm to Theradis Pharma.
- Theradis Pharma handles the order and sends study drugs to site.
- Inserm records delivery confirmation in the eCRF upon confirmation of AoR from Theradis Pharma.
- Inserm changes the status of the study drugs in the eCRF to “Available at Investigator’s” status and informs the Principal Investigator.

- The site can randomize patients.
- Inserm receives alert e-mails from the eCRF when the site's stock of IMP is getting low.
- Inserm orders resupplies of study drugs after confirmation by sponsor.

1.4 Storage/Drug Accountability/Destruction of the IMP

The IMPs should be stored in room temperature between 10 - 30°C.
The site/pharmacy should:

- Monitor the temperature every working day and fill in the temperature log (NorCrin template LM 2.13.2 (ISF 7.5))
- Conduct Drug Accountability and fill in the Drug Accountability Form (NorCrin template LM 2.13.3 (ISF 7.6))
- Conduct Drug Reconciliation and fill in the Drug Reconciliation Form (NorCrin template LM 2.13.6 (ISF 7.6))
- Do NOT destroy any IMPs until the monitor/sponsor has given permission. Upon request from the monitor/sponsor the site should complete the Destruction Form (NorCrin template LM 2.13.7 (ISF 7.7)) and destroy the IMPs according to local procedures.